肝内胆管癌的分子机制与治疗研究进展
Research Advances in the Molecular Mechanisms and Treatment of Intrahepatic Cholangiocarcinoma
DOI: 10.12677/wjcr.2026.162009, PDF,   
作者: 马 雨：重庆理工大学药学与生物工程学院，重庆
关键词: 信号通路；关键基因改变；治疗；Signaling Pathway； Key Gene Alteration； Treatment
摘要: 肝内胆管癌(iCCA)具有发病隐匿、易转移的特点，多数患者确诊时已处于晚期。其发生发展与IDH1/2突变、FGFR2融合等关键基因改变及PI3K/AKT、Wnt/β-catenin、Hippo/YAP等信号通路异常密切相关。目前治疗以手术切除联合化疗为主，但疗效有限。近年来，针对特定分子靶点(如IDH1/2、FGFR2)的靶向药物(如培米替尼、艾伏尼布)已获批应用，为患者提供了新的治疗选择。
Abstract: Intrahepatic Cholangiocarcinoma (iCCA) is characterized by insidious onset and easy metastasis. Most patients are already in the advanced stage at the time of diagnosis. Its occurrence and development are closely related to key gene alterations such as IDH1/2 mutations and FGFR2 fusions, as well as abnormalities in signaling pathways such as PI3K/AKT, Wnt/β-catenin, and Hippo/YAP. Currently, the main treatment is surgical resection combined with chemotherapy, but the efficacy is limited. In recent years, targeted drugs (such as pemigatinib and ivosidenib) targeting specific molecular targets (such as IDH1/2 and FGFR2) have been approved for use, providing new treatment options for patients.
文章引用：马雨. 肝内胆管癌的分子机制与治疗研究进展[J]. 世界肿瘤研究, 2026, 16(2): 68-76. https://doi.org/10.12677/wjcr.2026.162009

参考文献

[1] Rodrigues, P.M., Olaizola, P., Paiva, N.A., Olaizola, I., Agirre-Lizaso, A., Landa, A., et al. (2021) Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 16, 433-463. [Google Scholar] [CrossRef] [PubMed]
[2] Ilyas, S.I., Khan, S.A., Hallemeier, C.L., Kelley, R.K. and Gores, G.J. (2017) Cholangiocarcinoma—Evolving Concepts and Therapeutic Strategies. Nature Reviews Clinical Oncology, 15, 95-111. [Google Scholar] [CrossRef] [PubMed]
[3] Cillo, U., Fondevila, C., Donadon, M., Gringeri, E., Mocchegiani, F., Schlitt, H.J., et al. (2019) Surgery for Cholangiocarcinoma. Liver International, 39, 143-155. [Google Scholar] [CrossRef] [PubMed]
[4] Moris, D., Palta, M., Kim, C., Allen, P.J., Morse, M.A. and Lidsky, M.E. (2022) Advances in the Treatment of Intrahepatic Cholangiocarcinoma: An Overview of the Current and Future Therapeutic Landscape for Clinicians. CA: A Cancer Journal for Clinicians, 73, 198-222. [Google Scholar] [CrossRef] [PubMed]
[5] Hadfield, M.J., DeCarli, K., Bash, K., Sun, G. and Almhanna, K. (2023) Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review. International Journal of Molecular Sciences, 25, Article 543. [Google Scholar] [CrossRef] [PubMed]
[6] Boerner, T., Drill, E., Pak, L.M., Nguyen, B., Sigel, C.S., Doussot, A., et al. (2021) Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 74, 1429-1444. [Google Scholar] [CrossRef] [PubMed]
[7] Pirozzi, C.J. and Yan, H. (2021) The Implications of IDH Mutations for Cancer Development and Therapy. Nature Reviews Clinical Oncology, 18, 645-661. [Google Scholar] [CrossRef] [PubMed]
[8] Wu, S., Huang, J., Dong, J. and Pan, D. (2003) Hippo Encodes a Ste-20 Family Protein Kinase That Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with Salvador and Warts. Cell, 114, 445-456. [Google Scholar] [CrossRef] [PubMed]
[9] Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A. and Pecqueur, C. (2021) Wild-type Isocitrate Dehydrogenase under the Spotlight in Glioblastoma. Oncogene, 41, 613-621. [Google Scholar] [CrossRef] [PubMed]
[10] Molenaar, R.J., Maciejewski, J.P., Wilmink, J.W. and van Noorden, C.J.F. (2018) Wild-Type and Mutated IDH1/2 Enzymes and Therapy Responses. Oncogene, 37, 1949-1960. [Google Scholar] [CrossRef] [PubMed]
[11] Lavacchi, D., Caliman, E., Rossi, G., Buttitta, E., Botteri, C., Fancelli, S., et al. (2022) Ivosidenib in IDH1-Mutated Cholangiocarcinoma: Clinical Evaluation and Future Directions. Pharmacology & Therapeutics, 237, Article ID: 108170. [Google Scholar] [CrossRef] [PubMed]
[12] Sumbly, V., Landry, I. and Rizzo, V. (2022) Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. Cureus, 14, e21018. [Google Scholar] [CrossRef] [PubMed]
[13] Boulter, L. and Ebrahimkhani, M.R. (2021) Build to Understand Biliary Oncogenesis via Organoids and FGFR2 Fusion Proteins. Journal of Hepatology, 75, 262-264. [Google Scholar] [CrossRef] [PubMed]
[14] Liu, S., Weng, J., Cao, M., Zhou, Q., Xu, M., Xu, W., et al. (2024) FGFR2 Fusion/Rearrangement Is Associated with Favorable Prognosis and Immunoactivation in Patients with Intrahepatic Cholangiocarcinoma. The Oncologist, 29, e1734-e1747. [Google Scholar] [CrossRef] [PubMed]
[15] Guo, B., Fan, Y., Li, D., Xia, F., Luo, C., Zhu, J., et al. (2025) Locoregional Gemcitabine plus Surufatinib and Camrelizumab in FGFR2-Non-Altered Intrahepatic Cholangiocarcinoma. Cell Reports Medicine, 6, Article ID: 102482. [Google Scholar] [CrossRef] 
[16] Katoh, M. (2018) Fibroblast Growth Factor Receptors as Treatment Targets in Clinical Oncology. Nature Reviews Clinical Oncology, 16, 105-122. [Google Scholar] [CrossRef] [PubMed]
[17] Vogel, A., Segatto, O., Stenzinger, A. and Saborowski, A. (2023) FGFR2 Inhibition in Cholangiocarcinoma. Annual Review of Medicine, 74, 293-306. [Google Scholar] [CrossRef] [PubMed]
[18] Angerilli, V., Fornaro, L., Pepe, F., Rossi, S.M., Perrone, G., Malapelle, U., et al. (2023) FGFR2 Testing in Cholangiocarcinoma: Translating Molecular Studies into Clinical Practice. Pathologica, 115, 71-82. [Google Scholar] [CrossRef] [PubMed]
[19] Aure, M.H., Symonds, J.M., Villapudua, C.U., Dodge, J.T., Werner, S., Knosp, W.M., et al. (2023) FGFR2 Is Essential for Salivary Gland Duct Homeostasis and MAPK-Dependent Seromucous Acinar Cell Differentiation. Nature Communications, 14, Article No. 6485. [Google Scholar] [CrossRef] [PubMed]
[20] Rao, S., Goyal, A., Johnson, A., Sadashiva, N., Kulanthaivelu, K., Vazhayil, V., et al. (2024) MAPK Pathway Alterations in Polymorphous Low-Grade Neuroepithelial Tumor of the Young: Diagnostic Considerations. Brain Tumor Pathology, 41, 109-116. [Google Scholar] [CrossRef] [PubMed]
[21] Pfaff, M.J., Xue, K., Li, L., Horowitz, M.C., Steinbacher, D.M. and Eswarakumar, J.V.P. (2016) FGFR2c-Mediated ERK-MAPK Activity Regulates Coronal Suture Development. Developmental Biology, 415, 242-250. [Google Scholar] [CrossRef] [PubMed]
[22] Riccetti, M.R., Green, J., Taylor, T.J. and Perl, A.T. (2024) Prenatal FGFR2 Signaling via PI3K/AKT Specifies the PDGFRA+ Myofibroblast. American Journal of Respiratory Cell and Molecular Biology, 70, 63-77. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, J., Xin, C., Yin, G. and Li, J. (2023) Taraxasterol Suppresses the Proliferation and Tumor Growth of Androgen-Independent Prostate Cancer Cells through the FGFR2-PI3K/AKT Signaling Pathway. Scientific Reports, 13, Article No. 13072. [Google Scholar] [CrossRef] [PubMed]
[24] Martin-Serrano, M.A., Kepecs, B., Torres-Martin, M., Bramel, E.R., Haber, P.K., Merritt, E., et al. (2022) Novel Microenvironment-Based Classification of Intrahepatic Cholangiocarcinoma with Therapeutic Implications. Gut, 72, 736-748. [Google Scholar] [CrossRef] [PubMed]
[25] Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., et al. (2024) An Open-Label Study of Pemigatinib in Cholangiocarcinoma: Final Results from Fight-202. ESMO Open, 9, Article ID: 103488. [Google Scholar] [CrossRef] [PubMed]
[26] Javle, M., Roychowdhury, S., Kelley, R.K., Sadeghi, S., Macarulla, T., Weiss, K.H., et al. (2021) Infigratinib (BGJ398) in Previously Treated Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Mature Results from a Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Gastroenterology & Hepatology, 6, 803-815. [Google Scholar] [CrossRef] [PubMed]
[27] Liu, L., He, Y., Dong, P., Ma, L., Wang, Z., Liu, X., et al. (2016) Protein Tyrosine Phosphatase PTP4A1 Promotes Proliferation and Epithelial-Mesenchymal Transition in Intrahepatic Cholangiocarcinoma via the PI3K/AKT Pathway. Oncotarget, 7, 75210-75220. [Google Scholar] [CrossRef] [PubMed]
[28] Zhu, X., Song, X., Xie, K., Zhang, X., He, W. and Liu, F. (2017) Osthole Induces Apoptosis and Suppresses Proliferation via the PI3K/Akt Pathway in Intrahepatic Cholangiocarcinoma. International Journal of Molecular Medicine, 40, 1143-1151. [Google Scholar] [CrossRef] [PubMed]
[29] Xie, K., Nian, J., Zhu, X., Geng, X. and Liu, F. (2015) Modulatory Role of Garlicin in Migration and Invasion of Intrahepatic Cholangiocarcinoma via PI3K/AKT Pathway. International Journal of Clinical and Experimental Pathology, 8, 14028-14033.
[30] Song, F., Chen, F., Wu, S., Hu, B., Liang, X., Yang, H., et al. (2021) Mucin 1 Promotes Tumor Progression through Activating Wnt/β-Catenin Signaling Pathway in Intrahepatic Cholangiocarcinoma. Journal of Cancer, 12, 6937-6947. [Google Scholar] [CrossRef] [PubMed]
[31] Wei, Y., Chen, W., Li, Z., Xie, K. and Liu, F. (2022) EIF3H stabilizes CCND1 to Promotes Intrahepatic Cholangiocarcinoma Progression via Wnt/β‐Catenin Signaling. The FASEB Journal, 36, e22647. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, H., Dong, X., Ding, X., Liu, G., Yang, F., Song, Q., et al. (2023) Bufalin Targeting CAMKK2 Inhibits the Occurrence and Development of Intrahepatic Cholangiocarcinoma through Wnt/β-Catenin Signal Pathway. Journal of Translational Medicine, 21, Article No. 900. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, Y., Xu, H., Cui, G., Liang, B., Chen, X., Ko, S., et al. (2022) β-Catenin Sustains and Is Required for Yes-Associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 163, 481-494. [Google Scholar] [CrossRef] [PubMed]
[34] Taniguchi, K., Wu, L., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F., et al. (2015) A Gp130-Src-YAP Module Links Inflammation to Epithelial Regeneration. Nature, 519, 57-62. [Google Scholar] [CrossRef] [PubMed]
[35] Kim, S.H. and Park, J. (2019) IDH2 Deficiency Impairs Cutaneous Wound Healing via Ros-Dependent Apoptosis. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1865, Article ID: 165523. [Google Scholar] [CrossRef] [PubMed]
[36] Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R.E., Longarini, R., Stagno, A.M., et al. (2022) Clinical Treatment of Cholangiocarcinoma: An Updated Comprehensive Review. Annals of Hepatology, 27, Article ID: 100737. [Google Scholar] [CrossRef] [PubMed]
[37] Roy, S., Glaser, S. and Chakraborty, S. (2019) Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. Frontiers in Medicine, 6, Article 293. [Google Scholar] [CrossRef] [PubMed]
[38] Fong, Z.V., Brownlee, S.A., Qadan, M. and Tanabe, K.K. (2021) The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Annals of Surgical Oncology, 28, 2660-2674. [Google Scholar] [CrossRef] [PubMed]
[39] Park, J.O., Oh, D., Hsu, C., Chen, J., Chen, L., Orlando, M., et al. (2015) Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Research and Treatment, 47, 343-361. [Google Scholar] [CrossRef] [PubMed]
[40] Oh, D., He, A.R., Bouattour, M., Okusaka, T., Qin, S., Chen, L., et al. (2024) Durvalumab or Placebo Plus Gemcitabine and Cisplatin in Participants with Advanced Biliary Tract Cancer (TOPAZ-1): Updated Overall Survival from a Randomised Phase 3 Study. The Lancet Gastroenterology & Hepatology, 9, 694-704. [Google Scholar] [CrossRef] [PubMed]
[41] Sarabi, M. and Artru, P. (2025) Biliary Tract Cancers: Topaz-1 Up-Date, a Practice Changing Study. Hepatobiliary Surgery and Nutrition, 14, 1009-1011. [Google Scholar] [CrossRef] 
[42] Burris, H.A., Okusaka, T., Vogel, A., Lee, M.A., Takahashi, H., Breder, V., et al. (2024) Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1): Patient-Reported Outcomes from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 25, 626-635. [Google Scholar] [CrossRef] [PubMed]
[43] Wang, J., Xu, Y., Hong, B., Hou, Q., Chen, W., Zhang, W., et al. (2025) PD-1/PD-L1 Inhibitors Plus Chemotherapy versus Chemotherapy Alone as the First Line Treatment for Advanced Biliary Tract Cancer: A Pooled Analysis of KEYNOTE-966 and TOPAZ-1 Trails. World Journal of Surgical Oncology, 23, Article No. 228. [Google Scholar] [CrossRef] [PubMed]
[44] Almhanna, K. (2024) Immune Checkpoint Inhibitors in Combination with Chemotherapy for Patients with Biliary Tract Cancer: What Did We Learn from TOPAZ-1 and Keynote-966. Translational Cancer Research, 13, 22-24. [Google Scholar] [CrossRef] [PubMed]
[45] Igata, Y., Kudo, M., Kojima, M., Kami, S., Aoki, K., Satake, T., et al. (2024) Conversion Surgery after Gemcitabine and Cisplatin Plus Durvalumab for Advanced Intrahepatic Cholangiocarcinoma: A Case Report. World Journal of Clinical Cases, 12, 6721-6727. [Google Scholar] [CrossRef] [PubMed]
[46] Phuna, Z.X., Kumar, P.A., Haroun, E., Dutta, D. and Lim, S.H. (2024) Antibody-Drug Conjugates: Principles and Opportunities. Life Sciences, 347, Article ID: 122676. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., et al. (2025) Antibody-Drug Conjugates (ADCs): Current and Future Biopharmaceuticals. Journal of Hematology & Oncology, 18, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[48] Macarulla, T., Neuzillet, C., Prager, G.W., Rimassa, L. and Bridgewater, J. (2025) Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review. Oncology and Therapy, 13, 939-962. [Google Scholar] [CrossRef] 
[49] Ballestín, P., López de Sá, A., Díaz-Tejeiro, C., Paniagua-Herranz, L., Sanvicente, A., López-Cade, I., et al. (2025) Understanding the Toxicity Profile of Approved ADCs. Pharmaceutics, 17, Article 258. [Google Scholar] [CrossRef] [PubMed]
[50] Bao, X., Chen, Z., Xiong, J., Yang, Z. and Zhang, N. (2025) Advanced Cholangiocarcinoma with Human Epidermal Growth Factor Receptor 2 (HER2) Amplification Treated with Trastuzumab Deruxtecan (T-DXd): A Case Report. Medicine, 104, e44094. [Google Scholar] [CrossRef] 
[51] Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., et al. (2024) Tisotumab Vedotin as Second-or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine, 391, 44-55. [Google Scholar] [CrossRef] [PubMed]
[52] Song, X., Li, R., Wang, H., Song, P., Guo, W. and Chen, Z. (2022) Tisotumab Vedotin for the Treatment of Cervical Carcinoma. Drugs of Today, 58, 213-222. [Google Scholar] [CrossRef] [PubMed]
[53] Markham, A. (2021) Tisotumab Vedotin: First Approval. Drugs, 81, 2141-2147. [Google Scholar] [CrossRef] [PubMed]

为你推荐